193 related articles for article (PubMed ID: 3875319)
1. Involvement of complement in psoriasis and atopic dermatitis--measurement of C3a and C5a, C3, C4 and C1 inactivator.
Kapp A; Wokalek H; Schöpf E
Arch Dermatol Res; 1985; 277(5):359-61. PubMed ID: 3875319
[TBL] [Abstract][Full Text] [Related]
2. Involvement of complement in atopic dermatitis.
Kapp A; Schöpf E
Acta Derm Venereol Suppl (Stockh); 1985; 114():152-4. PubMed ID: 3923750
[TBL] [Abstract][Full Text] [Related]
3. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
Takematsu H; Ohkohchi K; Tagami H
Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
[TBL] [Abstract][Full Text] [Related]
5. Complement activation during storage of whole blood, red cells, plasma, and buffy coat.
Hyllner M; Arnestad JP; Bengtson JP; Rydberg L; Bengtsson A
Transfusion; 1997 Mar; 37(3):264-8. PubMed ID: 9122898
[TBL] [Abstract][Full Text] [Related]
6. Anaphylatoxin generation in multisystem organ failure.
Heideman M; Hugli TE
J Trauma; 1984 Dec; 24(12):1038-43. PubMed ID: 6334754
[TBL] [Abstract][Full Text] [Related]
7. C3, C5 components and C3a, C4a, and C5a fragments of the complement system.
Janatova J
Methods Enzymol; 1988; 162():579-625. PubMed ID: 3265757
[No Abstract] [Full Text] [Related]
8. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
Hack CE; Nuijens JH; Felt-Bersma RJ; Schreuder WO; Eerenberg-Belmer AJ; Paardekooper J; Bronsveld W; Thijs LG
Am J Med; 1989 Jan; 86(1):20-6. PubMed ID: 2783358
[TBL] [Abstract][Full Text] [Related]
9. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
[TBL] [Abstract][Full Text] [Related]
10. Detection of the terminal complement complex in patient plasma following acute myocardial infarction.
Langlois PF; Gawryl MS
Atherosclerosis; 1988 Mar; 70(1-2):95-105. PubMed ID: 3258520
[TBL] [Abstract][Full Text] [Related]
11. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
[TBL] [Abstract][Full Text] [Related]
12. Complement levels of C4, C3C, factor B, and C1 inactivator in peripheral and retroplacental blood of parturient women with EPH gestosis.
Zdanowicz A; Jabłońska E; Pietruska Z; Bielecki M
Ann Med Univ Bialyst Pol; 1993; 38(1):60-7. PubMed ID: 7922487
[TBL] [Abstract][Full Text] [Related]
13. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
[No Abstract] [Full Text] [Related]
14. Increased anaphylatoxins (C3a and C4a) in psoriatic sera.
Ohkohchi K; Takematsu H; Tagami H
Br J Dermatol; 1985 Aug; 113(2):189-96. PubMed ID: 3875363
[TBL] [Abstract][Full Text] [Related]
15. Anaphylatoxin levels in human aqueous humor.
Mondino BJ; Sumner H
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
[TBL] [Abstract][Full Text] [Related]
16. Complement profile in a C1 inhibitor deficient family.
Sayama K; Shiraishi S; Miki Y
Br J Dermatol; 1985 Dec; 113(6):737-43. PubMed ID: 4096884
[TBL] [Abstract][Full Text] [Related]
17. Complement factors and acute phase reactants in the Guillain-Barré syndrome.
Tönnessen TI; Nyland H; Aarli JA
Eur Neurol; 1982; 21(2):124-8. PubMed ID: 6920298
[TBL] [Abstract][Full Text] [Related]
18. Complement activation in patients with systemic lupus erythematosus without nephritis.
Mollnes TE; Haga HJ; Brun JG; Nielsen EW; Sjöholm A; Sturfeldt G; Mårtensson U; Bergh K; Rekvig OP
Rheumatology (Oxford); 1999 Oct; 38(10):933-40. PubMed ID: 10534542
[TBL] [Abstract][Full Text] [Related]
19. The effect of aging on complement activity (CH50) and complement protein levels.
Nagaki K; Hiramatsu S; Inai S; Sasaki A
J Clin Lab Immunol; 1980 Jan; 3(1):45-50. PubMed ID: 7381926
[TBL] [Abstract][Full Text] [Related]
20. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
